Finally, while we believe that the most important results of this study are (i) identification of a BRCAness profile that is not associated with BRCA1 and (ii) association of this triple-positive ovarian cancer (FANCD2+/PARP+/P53+) with very early recurrence of ovarian cancer and therefore platinum resistance. This evidence concerns the gene TP53 and ovarian carcinoma.